Purpose of this Study
We are doing this study to find out if an experimental drug called XTX101 (the study drug) is a safe and effective option for people who have advanced tumors or metastatic microsatellite stable colorectal cancer. We want to see how well it works on its own and in combination with a drug called atezolizumab.
Who Can Participate?
Eligibility
Adults ages 18+ who have one of the following forms of cancer:<ul>
<li>Advanced solid tumors; OR</li>
<li>Metastic microsatellite stable colorectal cancer</li></ul>
For more information about who can join this study, please contact the study team at <a href= "mailto: gi-oncology-cru@dm.duke.edu">gi-oncology-cru@dm.duke.edu</a> or 919-668-1861.
<li>Advanced solid tumors; OR</li>
<li>Metastic microsatellite stable colorectal cancer</li></ul>
For more information about who can join this study, please contact the study team at <a href= "mailto: gi-oncology-cru@dm.duke.edu">gi-oncology-cru@dm.duke.edu</a> or 919-668-1861.
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
If you choose to join this study, you will:<ul>
<li>Get a random assignment (like a coin flip) to either take the study drug on its own or in combination with atezolizumab</li>
<li>Have a tumor biopsy done, if necessary</li>
<li>Have blood draws</li>
<li>Have imaging scans (CT or MRI)</li></ul>
<li>Get a random assignment (like a coin flip) to either take the study drug on its own or in combination with atezolizumab</li>
<li>Have a tumor biopsy done, if necessary</li>
<li>Have blood draws</li>
<li>Have imaging scans (CT or MRI)</li></ul>
Locations
Duke University Hospital
Compensation
No
Spanish Materials Available
Yes
Study Details
Full Title
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of Vilastobart (XTX101) Monotherapy and Vilastobart (XTX101) and Atezolizumab Combination Therapy in Patients with Advanced Solid Tumors
Principal Investigator
Nicholas
DeVito
Protocol Number
PRO00115574
NCT ID
NCT04896697
Phase
I/II
Enrollment Status
Open to Enrollment